Preclinical studies support the existing hypothesis that targeting other cancer-promoting pathway components (such as WEE1, MEK/MAPK, and PI3K) may enhance PARPis efficacy; in particular, while still preserving anti-tumor activity [86]. Here, MAP2K7 is linked to neoplasm.